Vantage Orian 1.5T the Latest System in Company’s Portfolio with Access to Advanced intelligent Clear-IQ Engine (AiCE) TUSTIN, Calif.–(BUSINESS WIRE)–Canon Medical Systems USA, Inc. has received 510(k) clearance on its Advanced intelligent Clear-IQ Engine (AiCE)* for the Vantage Orian 1.5T MR system, continuing to expand access to its new Deep Learning Reconstruction (DLR) […]
Author: Ken Dropiewski
FUJIFILM Sonosite Launches New Point-Of-Care Ultrasound System With Adaptable Form Factor, Embedded Workflow, And The Most Advanced Image Clarity Sonosite Has Ever Offered
BOTHELL, Wash., July 21, 2020 /PRNewswire/ — FUJIFILM Sonosite, Inc., specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger Fujifilm Healthcare portfolio, has announced the launch of the new Sonosite PX ultrasound system. Sonosite PX is the next generation in Sonosite POCUS, with the most advanced image clarity ever seen in […]
LifeSignals Wireless Medical Biosensor LP1250 receives FDA clearance
– World’s first single-use two channel ECG and heart rate biosensor provides 72-hour patient monitoring with remote data access in ambulatory, hospital and home settings FREMONT, Calif., July 21, 2020 /PRNewswire/ — LifeSignals Group, today announced USFDA 510(k) clearance has been received for their LifeSignals ECG Remote Monitoring Patch Platform. The LifeSignals […]
CVRx® Completes Enrollment of the BeAT-HF Phase III Randomized Clinical Trial, Continues to collect Morbidity and Mortality Outcomes
CVRx Enrolls the First Patient in a Post Market Heart Failure Registry MINNEAPOLIS, July 21, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced that the BeAT-HF phase III randomized clinical trial has completed enrollment in the post-market phase. CVRx has also enrolled the first patient in a heart failure (“HF”) […]
CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update
Achieved preliminary record total quarterly revenue of $9.8 million and product sales of $9.5 million, driven by demand for CytoSorb as a treatment of cytokine storm in COVID-19 infection and other illnesses. MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat […]
Spectral MD and the American College of Cardiology to Advance Care for Critical Limb Ischemia
Spectral MD and the ACC will collaborate to provide scientific oversight and assessment of the clinical value of Spectral MD’s DeepView technology to detect and assess critical limb ischemia DALLAS, July 21, 2020 /PRNewswire/ — Spectral MD and the American College of Cardiology (ACC) announced today that they will collaborate to investigate the […]
ViralClear Announces Formation of Its Scientific Advisory Board
Westport, CT, July 20, 2020 (GLOBE NEWSWIRE) — BioSig Subsidiary Enlists Seasoned Professionals in Emerging Infectious Diseases and Regulatory Development to Its Advisory Board ViralClear Pharmaceuticals is Currently in Phase II Trials with Its Lead Asset Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) […]
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
Los Angeles, CA, July 21, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announced the Company’s registration statement on Form S-1 relating to its equity credit line with Calvary Fund I LP has been ordered effective by the Securities and Exchange Commission. This equity […]
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
Collaboration will Combine MyoKardia’s Leading Precision Cardiovascular R&D Platform with Fulcrum’s Proprietary Product Engine to Identify Targets that Modulate Gene Expression BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious […]
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina
– Novel gene therapy designed to stimulate formation of new coronary blood vessels is being studied in patients with treatment-resistant angina with no remaining treatment options – July 21, 2020 07:00 AM Eastern Daylight Time MALVERN, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics today announced it has successfully dosed the first two patients in […]


